查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
NGS(RNA-Sep)RNA測序全球市場：按產品/服務（樣品製備,平台/耗材,服務,數據分析）,技術（SBS,SMRT,納米孔）,應用（從頭,表觀遺傳）典型,小RNA）,用戶,地區預測到2027
市場調查報告書
商品編碼
1270837

NGS(RNA-Sep)RNA測序全球市場：按產品/服務（樣品製備,平台/耗材,服務,數據分析）,技術（SBS,SMRT,納米孔）,應用（從頭,表觀遺傳）典型,小RNA）,用戶,地區預測到2027

NGS-based RNA-sequencing Market by Product & Services (Sample Preparation, Platforms & Consumables, Services, Data Analysis), Technology (SBS, SMRT, Nanopore), Application (De Novo, Epigenetics, small RNA), End-User, Region - Global Forecast to 2027
出版日期: | 出版商: MarketsandMarkets | 英文 202 Pages | 訂單完成後即時交付

價格
簡介目錄

全球 NGS RNA 測序 (RNA-Sep) 市場規模到 2027 年將達到 55 億美元，高於 2022 年的 25 億美元，複合年增長率為 17.2% 在預測期內預計將增長。

NGS RNA 測序 (RNA-Sep) 市場的增長主要是由於 RNA 測序相對於傳統技術的優勢、基因組測序成本的下降、政府增加對基因組學項目的資助以及涉及 RNA 測序的研究不斷擴大., 由於癌症患者數量的不斷增加，NGS在癌症研究中的應用不斷擴大，以及個性化醫療的快速增長。 另一方面，合格專業人員短缺、新興國家的最終用戶預算限制以及診斷測試中的標準化問題預計將限制市場增長。

“預計納米孔測序領域在預測期內將以顯著的複合年增長率增長”

按技術劃分，NGS RNA 測序 (RNA-Sep) 市場分為 SBS、離子半導體測序、SMRT 測序和納米孔測序。 納米孔測序部分預計將在 2022 年至 2027 年實現最高的複合年增長率。 納米孔測序是唯一具有直接 RNA 測序能力的測序技術。 與其他新一代測序技術相比，納米孔測序是對天然DNA和RNA進行單分子測序，可以檢測單個核甘酸的修飾，因此引物覆蓋了16S基因全長甚至整個核醣體操縱子。由於實時靶向測序、長讀取長度、全長 cDNA 讀取和結構變異的穩健檢測等優勢，用戶採用率正在增加。

“從應用來看，表達譜分析細分市場將在 2021 年佔據主導地位”

按應用，NGS RNA 測序 (RNA-Sep) 市場分為表達譜分析、小 RNA 測序、從頭轉錄組組裝和變異檢出轉錄組表觀遺傳學。 到 2021 年，表達譜分析部分將佔據 NGS (RNA-Sep) RNA 測序市場的最大份額。 代謝疾病、多發性硬化症等疾病的流行率不斷上升，預計將推動對錶達譜分析的需求。

“北美將在 2021 年主導市場”

NGS RNA 測序 (RNA-Sep) 市場按地區劃分為北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。 到 2021 年，北美將佔據 NGS（RNA-Sep）市場 RNA 測序的主要份額。 北美以政府支持、RNA 測序產品的進步、目標疾病的流行率增加、對癌症和罕見遺傳病的研究增加以及主要參與者在該地區的強大存在為主導。佔據了重要的市場份額。 然而，由於對研發的高度重視、NGS 產品和服務的成本降低以及主要市場參與者越來越關注加強其在亞太地區的影響力，亞太市場在預測期內將繼續增長。預計將以最高的複合年增長率增長。

內容

第一章介紹

第二章研究方法論

第 3 章執行摘要

第 4 章重要注意事項

第 5 章市場概述

  • 介紹
  • 市場動態
    • 司機
    • 約束因素
    • 機會
    • 任務

第 6 章 NGS RNA 測序（RNA-Sep）市場：按產品和服務分類

  • 介紹
  • RNA 測序 (RNA-Sep) 平台和耗材
  • 樣品製備產品
  • RNA 測序 (RNA-Sep) 服務
  • 數據分析/存儲/管理

第 7 章 NGS RNA 測序 (RNA-Sep) 市場：按技術分類

  • 介紹
  • SBS
  • 離子半導體測序
  • SMRT序列
  • 納米孔測序

第 8 章 NGS RNA 測序 (RNA-Sep) 市場：按應用

  • 介紹
  • 表達譜分析
  • 小RNA測序（RNA-Sep）
  • 從頭轉錄組組裝
  • 變異調用轉錄組表觀遺傳學

第 9 章 NGS RNA 測序（RNA-Sep）市場：最終用戶

  • 介紹
  • 研究和學術
  • 醫院和診所
  • 製藥和生物技術公司
  • 其他

第 10 章 NGS RNA 測序（RNA-Sep）市場：按地區

  • 介紹
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中東和非洲

第11章競爭格局

  • 概覽
  • 主要公司戰略/領先公司
  • 市場份額分析
  • 頂級市場公司的收入份額分析
  • 競爭領導力映射
  • 競爭場景

第12章公司簡介

  • 主要公司
    • ILLUMINA, INC.
    • QIAGEN N.V.
    • PERKINELMER, INC.
    • EUROFINS SCIENTIFIC
    • OXFORD NANOPORE TECHNOLOGIES
    • AGILENT TECHNOLOGIES, INC.
    • BGI GROUP
    • GENEWIZ（PART OF BROOKS AUTOMATION）
    • HAMILTON COMPANY
    • NUGEN TECHNOLOGIES（PART OF TECAN TRADING AG）
    • PSOMAGEN（FORMERLY KNOWN AS MACROGEN）
    • F. HOFFMANN-LA ROCHE AG
    • THERMO FISHER SCIENTIFIC, INC.
    • TAKARA BIO, INC.
    • PACIFIC BIOSCIENCES
  • 其他企業
    • ZYMO RESEARCH
    • LUCIGEN CORPORATION
    • GENOTYPIC TECHNOLOGY
    • OXFORD GENE TECHNOLOGY（PART OF SYSMEX）
    • BECTON, DICKINSON AND COMPANY

第13章 附錄

簡介目錄
Product Code: BT 5297

The global NGS-based RNA-sequencing market is projected to reach USD 5.5 billion by 2027 from USD 2.5 billion in 2022, at a CAGR of 17.2% during the forecast period. Growth in the NGS-based RNA-sequencing market is mainly driven by the advantages of RNA sequencing over conventional technologies, the decreasing cost of genome sequencing, increasing government funding to support genomics projects, growing research involving RNA sequencing, growing cancer cases, the increasing application of NGS in cancer research, and rapid growth in personalized medicine. On the other hand, a lack of qualified specialists, end-user budget constraints in developing countries, and standardization concerns in diagnostic testing are expected to limit the market growth.

"Nanopore sequencing segment is anticipated to grow at substantial CAGR during the forecast period."

Based on technology, the NGS-based RNA-sequencing market has been segmented into sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing. The nanopore sequencing segment is projected to register the highest CAGR from 2022 to 2027. Nanopore sequencing is the only sequencing technology with direct RNA-sequencing capabilities. The adoption of nanopore sequencing is increasing among end users due to its benefits as compared to other next-generation sequencing technologies, such as single-molecule sequencing of native DNA and RNA capable of detecting modifications in individual nucleotides allowing primers to cover the whole length of the 16S gene or even whole ribosomal operons, real-time targeted sequencing, large read lengths and full-length cDNA read, and reliable detection of structural variants.

"Expression profiling analysis applications segment dominated the market in 2021."

On the basis of application, the NGS-based RNA-sequencing market is segmented into expression profiling analysis, small RNA sequencing, de novo transcriptome assembly, and variant calling & transcriptome epigenetics. In 2021, the expression profiling analysis segment accounted for the largest share of the NGS-based RNA-sequencing market. The increasing prevalence of metabolic disorders, multiple sclerosis, and other diseases are expected to propel the demand for expression profiling analysis.

"North America held the dominant share of the market in 2021."

Geographically, the NGS-based RNA-sequencing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share of the NGS-based RNA-sequencing market. North America held the dominant share owing to the availability of government support, advancements in RNA sequencing products, the growing prevalence of target diseases, growing research on cancer and inherited rare diseases, and the strong presence of key players in the region. However, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to a significant focus on R&D, the decreasing costs of NGS products and services, and the increasing focus of major market players on strengthening their presence in the Asia Pacific.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Tier 1: 45%, Tier 2: 34%, Tier 3: 21%
  • By Designation - C-level: 47.0%, D-level: 33.0%, and Others: 20.0%
  • By Region - North America: 35%, Europe: 32%, Asia Pacific: 25%, Latin America: 6%, and the Middle East & Africa: 2%

List of Companies Profiled in the Report

    • Illumina, Inc. (US)
    • Thermo Fisher Scientific, Inc. (US)
    • PerkinElmer, Inc. (US)
    • QIAGEN N.V. (Netherlands)
    • Eurofins Scientific (UK)
    • Oxford Nanopore Technologies (UK)
    • Agilent Technologies, Inc. (US)
    • BGI Group (China)
    • GENEWIZ (US)
    • Hamilton Company (US)
    • NuGEN Technologies (US)
    • Psomagen, Inc. (South Korea)
    • F. Hoffmann-La Roche AG (Switzerland)
    • Takara Bio, Inc. (Japan)
    • Pacific Biosciences (US)
    • Zymo Research Corporation (US)
    • Lucigen Corporation (US)
    • Genotypic Technology (India)
    • Oxford Gene Technology (UK)
    • Becton, Dickinson and Company (US)

Research Coverage:

This report provides a detailed picture of the global NGS-based RNA-sequencing market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total NGS-based RNA-sequencing market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on NGS-based RNA-sequencing offered by the top 20 players in the NGS-based RNA-sequencing market. The report analyses the NGS-based RNA-sequencing market by product & service, technology, application, end user, and region.
  • Market Development: Comprehensive information about beneficial emerging markets. The report analyzes the markets for various NGS-based RNA-sequencing products and services across key geographic regions.
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the NGS-based RNA-sequencing market.
  • Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the NGS-based RNA-sequencing market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 REGIONAL SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Key data from primary sources
    • FIGURE 2 BREAKDOWN OF PRIMARIES
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 PRODUCT-BASED MARKET ESTIMATION
    • FIGURE 4 PRODUCT-BASED MARKET ESTIMATION
    • 2.2.2 APPLICATION-BASED MARKET ESTIMATION
    • FIGURE 5 APPLICATION-BASED MARKET ESTIMATION
  • 2.3 PRIMARY RESEARCH VALIDATION
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
    • FIGURE 7 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 8 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 9 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 10 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 11 NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 REGIONAL SNAPSHOT OF NGS-BASED RNA-SEQUENCING MARKET

4 PREMIUM INSIGHTS

  • 4.1 NGS-BASED RNA-SEQUENCING MARKET OVERVIEW
    • FIGURE 13 GROWING RESEARCH ACTIVITIES INVOLVING RNA-SEQUENCING TO DRIVE MARKET
  • 4.2 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY END USER AND COUNTRY (2021)
    • FIGURE 14 CHINA TO DOMINATE ASIA PACIFIC MARKET IN 2021
  • 4.3 GEOGRAPHICAL SNAPSHOT OF NGS-BASED RNA-SEQUENCING MARKET
    • FIGURE 15 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.4 NGS-BASED RNA-SEQUENCING MARKET, BY REGION
    • FIGURE 16 NORTH AMERICA TO DOMINATE NGS-BASED RNA-SEQUENCING MARKET IN 2027

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 17 NGS-BASED RNA-SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Decreasing costs of genome sequencing
    • FIGURE 18 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001-2021
      • 5.2.1.2 Advantages of RNA-sequencing over conventional technologies
      • 5.2.1.3 Increasing government funding to support genomics projects
      • 5.2.1.4 Growing research involving RNA-sequencing
      • 5.2.1.5 Rising cancer cases and increasing applications of NGS in cancer research
    • TABLE 1 CANCER INCIDENCE, 2020 VS. 2040
      • 5.2.1.6 Rapid growth in personalized medicine adoption
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Lack of qualified specialists
      • 5.2.2.2 End-user budget constraints in developing countries
      • 5.2.2.3 Standardization concerns of RNA-sequencing in diagnostic testing
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Adoption of blockchain technology and cloud computing
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Storage and interpretation of sequencing data
      • 5.2.4.2 Analysis of RNA-sequencing data to detect novel transcripts
      • 5.2.4.3 Ethical issues and challenges in testing procedure

6 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 2 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
  • 6.2 RNA-SEQUENCING PLATFORMS & CONSUMABLES
    • 6.2.1 INCREASING AVAILABILITY OF PLATFORMS AND GROWING CONSUMABLE USAGE TO ENSURE GROWTH
    • TABLE 3 RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 4 NORTH AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 5 EUROPE: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 6 ASIA PACIFIC: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 7 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 6.3 SAMPLE PREPARATION PRODUCTS
    • 6.3.1 SAMPLE PREPARATION TO BE FIRST STEP OF NGS WORKFLOW
    • TABLE 8 SAMPLE PREPARATION PRODUCTS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 9 NORTH AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 10 EUROPE: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 11 ASIA PACIFIC: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 12 LATIN AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.3.2 SAMPLE PREPARATION PRODUCTS, BY WORKFLOW
      • 6.3.2.1 Library preparation & target enrichment
      • 6.3.2.2 Quality control
    • 6.3.3 SAMPLE PREPARATION PRODUCTS, BY METHOD
      • 6.3.3.1 Manual sample preparation
      • 6.3.3.2 Microfluidic sample preparation
      • 6.3.3.3 Robotic liquid handling sample preparation
  • 6.4 RNA-SEQUENCING SERVICES
    • 6.4.1 INCREASING ADOPTION OF ADVANCED INFRASTRUCTURE AND EXPERTISE AMONG END USERS TO DRIVE DEMAND
    • TABLE 13 RNA-SEQUENCING SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 14 NORTH AMERICA: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 15 EUROPE: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 16 ASIA PACIFIC: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 17 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.5 DATA ANALYSIS, STORAGE & MANAGEMENT
    • 6.5.1 INTEGRATION OF CLOUD COMPUTING AND BIOINFORMATICS TO PROPEL MARKET
    • TABLE 18 DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 19 NORTH AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 20 EUROPE: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 21 ASIA PACIFIC: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 22 LATIN AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

7 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 23 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 7.2 SEQUENCING BY SYNTHESIS
    • 7.2.1 SBS TECHNOLOGY TO ENABLE HIGHEST PRODUCTION OF BASE PAIRS WITHIN SHORTEST TIME
    • TABLE 24 SEQUENCING BY SYNTHESIS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 25 NORTH AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 26 EUROPE: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 28 LATIN AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 ION SEMICONDUCTOR SEQUENCING
    • 7.3.1 ION SEMICONDUCTOR SEQUENCING PLATFORMS TO POSSESS HIGH-THROUGHPUT CAPABILITIES
    • TABLE 29 ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 30 NORTH AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 31 EUROPE: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 33 LATIN AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 SINGLE-MOLECULE REAL-TIME SEQUENCING
    • 7.4.1 SMRT SEQUENCING TO PRODUCE RESULTS IN SHORTER TIME AND LOWER COSTS
    • TABLE 34 SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 35 NORTH AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 36 EUROPE: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 38 LATIN AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.5 NANOPORE SEQUENCING
    • 7.5.1 NANOPORE SEQUENCING TO POSSESS DIRECT RNA-SEQUENCING CAPABILITIES
    • TABLE 39 NANOPORE SEQUENCING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 40 NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 41 EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 43 LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

8 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 44 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.2 EXPRESSION PROFILING ANALYSIS
    • 8.2.1 INCREASING NEED FOR IMPROVED PROGNOSIS OF PATIENTS TO PROPEL MARKET
    • TABLE 45 EXPRESSION PROFILING ANALYSIS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 46 NORTH AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 47 EUROPE: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 48 ASIA PACIFIC: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 49 LATIN AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 SMALL RNA-SEQUENCING
    • 8.3.1 RISING NEED FOR ACCURATE DIAGNOSTIC ANALYSIS TO SUPPORT MARKET
    • TABLE 50 SMALL RNA-SEQUENCING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 51 NORTH AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 52 EUROPE: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 54 LATIN AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.4 DE NOVO TRANSCRIPTOME ASSEMBLY
    • 8.4.1 INCREASING CANCER CASES TO DRIVE SEGMENT
    • TABLE 55 DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 56 NORTH AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 57 EUROPE: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 58 ASIA PACIFIC: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 59 LATIN AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.5 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS
    • 8.5.1 COMPLICATED RNA SEQUENCE DATA ANALYSIS TO RESTRAIN SEGMENT
    • TABLE 60 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 61 NORTH AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 62 EUROPE: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 64 LATIN AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

9 NGS-BASED RNA-SEQUENCING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 65 NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 RESEARCH & ACADEMIA
    • 9.2.1 INCREASING COLLABORATIONS WITH NGS PLAYERS AND RISING GOVERNMENT FUNDING TO PROPEL MARKET
    • TABLE 66 NGS-BASED RNA-SEQUENCING MARKET FOR RESEARCH & ACADEMIA, BY REGION, 2020-2027 (USD MILLION)
  • 9.3 HOSPITALS & CLINICS
    • 9.3.1 INCREASING ADOPTION OF NGS SYSTEMS TO DRIVE MARKET
    • TABLE 67 NGS-BASED RNA-SEQUENCING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020-2027 (USD MILLION)
  • 9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.4.1 CONSOLIDATION WITH NGS PLAYERS FOR TARGET THERAPIES TO PROPEL MARKET
    • TABLE 68 NGS-BASED RNA-SEQUENCING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION)
  • 9.5 OTHER END USERS
    • TABLE 69 NGS-BASED RNA-SEQUENCING MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)

10 NGS-BASED RNA-SEQUENCING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 70 NGS-BASED RNA-SEQUENCING MARKET, BY REGION, 2020-2027(USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 19 NORTH AMERICA: MARKET SNAPSHOT
    • TABLE 71 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027(USD MILLION)
    • TABLE 72 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 73 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 74 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 75 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Favorable funding scenario and growing R&D activity to drive market
    • TABLE 76 US: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 77 US: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 78 US: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Government initiatives for genome research to boost market
    • TABLE 79 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 80 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 81 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
  • 10.3 EUROPE
    • TABLE 82 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027(USD MILLION)
    • TABLE 83 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 84 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 85 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 86 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany to dominate European market during forecast period
    • TABLE 87 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 88 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 89 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Strong presence of NGS organizations and their initiatives to stimulate market
    • TABLE 90 UK: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 91 UK: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 92 UK: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Growing awareness of high-throughput sequencing in genetic characterization to accelerate growth
    • TABLE 93 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 94 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 95 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.3.4 REST OF EUROPE
    • TABLE 96 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 97 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 98 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 20 ASIA PACIFIC: MARKET SNAPSHOT
    • TABLE 99 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027(USD MILLION)
    • TABLE 100 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 101 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 102 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 103 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 Established players and favorable government initiatives to drive market
    • TABLE 104 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 105 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 106 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Growing awareness and rising incidence of genetic disorders to propel market
    • TABLE 107 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 108 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 109 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Rising interest of companies for collaborations to drive market
    • TABLE 110 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 111 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 112 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 113 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 114 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 115 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 116 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027(USD MILLION)
    • TABLE 117 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 118 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 119 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 120 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)
    • 10.5.1 BRAZIL
      • 10.5.1.1 High HIV prevalence to drive demand for NGS in research
    • TABLE 121 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 122 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 123 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.5.2 MEXICO
      • 10.5.2.1 Economic growth and support for infrastructural development to propel market
    • TABLE 124 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 125 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 126 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.5.3 REST OF LATIN AMERICA
    • TABLE 127 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 128 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 129 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 LACK OF INFRASTRUCTURE TO RESTRAIN MARKET
    • TABLE 130 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 131 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 132 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 133 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 21 KEY DEVELOPMENTS IN NGS-BASED RNA-SEQUENCING MARKET, 2019-2022
  • 11.3 MARKET SHARE ANALYSIS
    • FIGURE 22 NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2021
    • TABLE 134 NGS-BASED RNA-SEQUENCING MARKET: DEGREE OF COMPETITION
  • 11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 11.5 COMPETITIVE LEADERSHIP MAPPING
    • 11.5.1 TERMINOLOGY/NOMENCLATURE
      • 11.5.1.1 Visionary leaders
      • 11.5.1.2 Innovators
      • 11.5.1.3 Dynamic differentiators
      • 11.5.1.4 Emerging companies
    • FIGURE 24 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (OVERALL MARKET)
    • FIGURE 25 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (SMES/START-UPS)
  • 11.6 COMPETITIVE SCENARIO
    • TABLE 135 NGS-BASED RNA-SEQUENCING MARKET: PRODUCT/SERVICE LAUNCHES
    • TABLE 136 NGS-BASED RNA-SEQUENCING MARKET: DEALS
    • TABLE 137 NGS-BASED RNA-SEQUENCING MARKET: OTHER DEVELOPMENTS

12 COMPANY PROFILES

  • (Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)**
  • 12.1 KEY PLAYERS
    • 12.1.1 ILLUMINA, INC.
    • TABLE 138 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 26 ILLUMINA, INC.: COMPANY SNAPSHOT, 2021
    • TABLE 139 ILLUMINA, INC.: PRODUCT LAUNCHES
    • TABLE 140 ILLUMINA, INC.: DEALS
    • TABLE 141 ILLUMINA, INC.: OTHER DEVELOPMENTS
    • 12.1.2 QIAGEN N.V.
    • TABLE 142 QIAGEN N.V.: COMPANY OVERVIEW
    • FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT, 2021
    • TABLE 143 QIAGEN N.V.: PRODUCT LAUNCHES & ENHANCEMENTS
    • TABLE 144 QIAGEN N.V.: DEALS
    • 12.1.3 PERKINELMER, INC.
    • TABLE 145 PERKINELMER, INC.: COMPANY OVERVIEW
    • FIGURE 28 PERKINELMER, INC.: COMPANY SNAPSHOT, 2021
    • TABLE 146 PERKINELMER, INC.: PRODUCT LAUNCHES
    • 12.1.4 EUROFINS SCIENTIFIC
    • TABLE 147 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
    • FIGURE 29 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT, 2021
    • TABLE 148 EUROFINS SCIENTIFIC: DEALS
    • 12.1.5 OXFORD NANOPORE TECHNOLOGIES
    • TABLE 149 OXFORD NANOPORE TECHNOLOGIES: COMPANY OVERVIEW
    • TABLE 150 OXFORD NANOPORE TECHNOLOGIES: PRODUCT LAUNCHES
    • TABLE 151 OXFORD NANOPORE TECHNOLOGIES: DEALS
    • TABLE 152 OXFORD NANOPORE TECHNOLOGIES: OTHER DEVELOPMENTS
    • 12.1.6 AGILENT TECHNOLOGIES, INC.
    • TABLE 153 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
    • FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT, 2021
    • 12.1.7 BGI GROUP
    • TABLE 154 BGI GROUP: COMPANY OVERVIEW
    • TABLE 155 BGI GROUP: DEALS
    • 12.1.8 GENEWIZ (PART OF BROOKS AUTOMATION)
    • TABLE 156 GENEWIZ: COMPANY OVERVIEW
    • TABLE 157 GENEWIZ: SERVICES LAUNCHED
    • 12.1.9 HAMILTON COMPANY
    • TABLE 158 HAMILTON COMPANY: COMPANY OVERVIEW
    • 12.1.10 NUGEN TECHNOLOGIES (PART OF TECAN TRADING AG)
    • TABLE 159 NUGEN TECHNOLOGIES: COMPANY OVERVIEW
    • 12.1.11 PSOMAGEN (FORMERLY KNOWN AS MACROGEN)
    • TABLE 160 PSOMAGEN: COMPANY OVERVIEW
    • 12.1.12 F. HOFFMANN-LA ROCHE AG
    • TABLE 161 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
    • FIGURE 31 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT, 2021
    • TABLE 162 F. HOFFMANN-LA ROCHE AG: DEALS
    • 12.1.13 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 163 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW
    • FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT, 2021
    • TABLE 164 THERMO FISHER SCIENTIFIC, INC.: DEALS
    • 12.1.14 TAKARA BIO, INC.
    • TABLE 165 TAKARA BIO, INC.: COMPANY OVERVIEW
    • FIGURE 33 TAKARA BIO, INC.: COMPANY SNAPSHOT, 2021
    • 12.1.15 PACIFIC BIOSCIENCES
    • TABLE 166 PACIFIC BIOSCIENCES: COMPANY OVERVIEW
    • FIGURE 34 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT, 2021
  • 12.2 OTHER PLAYERS
    • 12.2.1 ZYMO RESEARCH
    • 12.2.2 LUCIGEN CORPORATION
    • 12.2.3 GENOTYPIC TECHNOLOGY
    • 12.2.4 OXFORD GENE TECHNOLOGY (PART OF SYSMEX)
    • 12.2.5 BECTON, DICKINSON AND COMPANY
  • *Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)** might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS